



Clinical trial results:

A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects

Summary

EudraCT number	2009-017950-11
Trial protocol	ES DE FR GB IT
Global end of trial date	27 December 2016

Results information

Result version number	v1 (current)
This version publication date	30 December 2017
First version publication date	30 December 2017

Trial information

Trial identification

Sponsor protocol code	113086
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	ViiV Healthcare
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 July 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 December 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate the antiviral activity of GSK1349572 50 mg administered once daily compared to RAL 400 mg twice daily over 48 weeks in HIV-1 infected therapy naïve subjects

Protection of trial subjects:

An Independent Data Monitoring Committee (IDMC) was utilized in this study to ensure external objective medical and/or statistical review of safety and/or efficacy issues in order to protect the ethical and safety interests of participants and to protect the scientific validity of the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 October 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 37
Country: Number of subjects enrolled	Canada: 61
Country: Number of subjects enrolled	France: 93
Country: Number of subjects enrolled	Germany: 95
Country: Number of subjects enrolled	Italy: 48
Country: Number of subjects enrolled	Russian Federation: 90
Country: Number of subjects enrolled	Spain: 242
Country: Number of subjects enrolled	United Kingdom: 17
Country: Number of subjects enrolled	United States: 139
Worldwide total number of subjects	822
EEA total number of subjects	495

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	816
From 65 to 84 years	6
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This was a randomized, parallel group, non-inferiority study to demonstrate the antiviral activity of Dolutegravir. Participants were enrolled from 9 countries. Participants in Dolutegravir arm who completed 96 Weeks double-blind phase continued to receive Dolutegravir in open-label phase, until dolutegravir was locally available commercially.

Pre-assignment

Screening details:

Total 1035 participants were screened; 827 participants were randomized, and 822 participants entered the treatment period. Of the 5 participants who were randomized but not treated with investigational product, 4 withdrew consent and 1 was randomized in error. 338 participants were enrolled in open label phase to receive Dolutegravir.

Period 1

Period 1 title	Double-blind Phase: 96 Weeks Duration
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	DTG 50 mg once a day

Arm description:

Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/(3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.

Arm type	Experimental
Investigational medicinal product name	Dolutegravir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received Dolutegravir 50 mg once a day for 96 weeks in double-blind treatment phase. Participants who completed 96 weeks of the treatment phase were given the opportunity to receive Dolutegravir 50 mg once a day during an Open-label Phase of the study.

Investigational medicinal product name	Tenofovir/Emtricitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received Tenofovir/Emtricitabine fixed-dose combination as a background therapy.

Investigational medicinal product name	Abacavir/Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received Abacavir/Lamivudine fixed-dose combination as a background therapy.

Arm title	RTG 400 mg BID
Arm description: Participants received RTG 400 mg BID in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.	
Arm type	Active comparator
Investigational medicinal product name	Raltegravir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Participants received Raltegravir 400 mg BID for 96 weeks in double-blind treatment phase.	
Investigational medicinal product name	Tenofovir/Emtricitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Participants received Tenofovir/Emtricitabine fixed-dose combination as a background therapy.	
Investigational medicinal product name	Abacavir/Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Participants received Abacavir/Lamivudine fixed-dose combination as a background therapy.	

Number of subjects in period 1	DTG 50 mg once a day	RTG 400 mg BID
Started	411	411
Completed	304	332
Not completed	107	79
Adverse event, serious fatal	1	1
Consent withdrawn by subject	18	14
Physician decision	3	-
Met Protocol-defined Stopping Criteria	6	3
Adverse event, non-fatal	11	6
Lost to follow-up	22	10
Study Closed/Terminated	6	4
Lack of efficacy	22	25
Protocol deviation	18	16

Period 2

Period 2 title	Open-label Phase: median of 1267 days
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	DTG 50 mg once a day (Open-label)
------------------	-----------------------------------

Arm description:

Participants who successfully completed 96 weeks of double blind phase continued to receive DTG 50 mg once a day during open label phase, until dolutegravir was locally available commercially. Participants received DTG 50 mg once a day in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.

Arm type	Experimental
Investigational medicinal product name	Dolutegravir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received Dolutegravir 50 mg once a day for 96 weeks in double-blind treatment phase. Participants who completed 96 weeks of the treatment phase were given the opportunity to receive Dolutegravir 50 mg once a day during an Open-label Phase of the study.

Investigational medicinal product name	Abacavir/Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received Abacavir/Lamivudine fixed-dose combination as a background therapy.

Investigational medicinal product name	Tenofovir/Emtricitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received Tenofovir/Emtricitabine fixed-dose combination as a background therapy.

Number of subjects in period 2	DTG 50 mg once a day (Open-label)
Started	338
Completed	294
Not completed	44
Consent withdrawn by subject	8
Physician decision	3
Met Protocol-defined Stopping Criteria	4
Adverse event, non-fatal	4
Lost to follow-up	15

Lack of efficacy	5
Protocol deviation	5

Baseline characteristics

Reporting groups

Reporting group title	DTG 50 mg once a day
-----------------------	----------------------

Reporting group description:

Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/(3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.

Reporting group title	RTG 400 mg BID
-----------------------	----------------

Reporting group description:

Participants received RTG 400 mg BID in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.

Reporting group values	DTG 50 mg once a day	RTG 400 mg BID	Total
Number of subjects	411	411	822
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	37.3	36.6	
standard deviation	± 9.19	± 10.02	-
Gender categorical			
Units:			
Female	63	56	119
Male	348	355	703
Race, Customized			
Units: Subjects			
African American/African Heritage (Her)	49	39	88
American Indian or Alaska Native	7	9	16
Central/South Asian Her	2	0	2
Japanese/East Asian Her/South East Asian Her	4	10	14
Native Hawaiian or other Pacific Islander	2	0	2
White	346	352	698
African American/African Her and Asian and White	1	0	1
Asian and White	0	1	1

End points

End points reporting groups

Reporting group title	DTG 50 mg once a day
Reporting group description: Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/(3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.	
Reporting group title	RTG 400 mg BID
Reporting group description: Participants received RTG 400 mg BID in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.	
Reporting group title	DTG 50 mg once a day (Open-label)
Reporting group description: Participants who successfully completed 96 weeks of double blind phase continued to receive DTG 50 mg once a day during open label phase, until dolutegravir was locally available commercially. Participants received DTG 50 mg once a day in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.	

Primary: Percentage of participants with Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 copies (c)/milliliter (mL) through Week 48

End point title	Percentage of participants with Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 copies (c)/milliliter (mL) through Week 48
End point description: Percentage of participants with plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) with <50 c/mL was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) snapshot algorithm. The algorithm treats all participants without HIV-1 RNA data as non-responders, as well as participants who switch their concomitant Antiretroviral Therapy (ART) prior to Week 48 as follows: background ART substitutions not permitted per study; background ART substitutions permitted per study unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the subject was on-treatment. Intent-to-Treat Exposed (ITT-E) Population comprised all randomized participants who received at least one dose of study medication.	
End point type	Primary
End point timeframe: Baseline up to Week 48	

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[1]	411		
Units: Percentage of participants				
number (not applicable)	88	85		

Notes:

[1] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	
Analysis was based on Cochran-Mantel Haenszel stratified analysis adjusted for the following Baseline stratification factors: Baseline HIV-1 RNA and background dual NRTI.	
Comparison groups	DTG 50 mg once a day v RTG 400 mg BID
Number of subjects included in analysis	822
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[2]
Parameter estimate	Difference in percentage
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	7.1

Notes:

[2] - Non-inferiority could be concluded if the lower bound of a two-sided 95% confidence interval for the difference (DTG - RAL) in percentages between the two treatment arms was > -10%.

Secondary: Number of participants with detectable HIV-1 virus that has genotypic or phenotypic evidence of INI resistance

End point title	Number of participants with detectable HIV-1 virus that has genotypic or phenotypic evidence of INI resistance
End point description:	
Number of participants with detectable virus that has genotypic or phenotypic evidence of Integrase Inhibitor (INI) resistance were assessed at Week 48 and Week 96. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the deoxyribonucleic acid (DNA) of the host cell.	
End point type	Secondary
End point timeframe:	
Week 48 and Week 96	

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[3]	411		
Units: Participants				
Week 48, genotypic	0	1		
Week 48, phenotypic	1	2		
Week 96, genotypic	0	1		
Week 96, phenotypic	1	2		

Notes:

[3] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA <50 c/mL

End point title	Number of participants with plasma HIV-1 RNA <50 c/mL
-----------------	---

End point description:

The number of participants with plasma HIV-1 RNA level <50 c/mL was assessed at Week 96.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 96

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[4]	411		
Units: Participants	332	314		

Notes:

[4] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA <400 c/mL

End point title	Number of participants with plasma HIV-1 RNA <400 c/mL
-----------------	--

End point description:

The number of participants with plasma HIV-1 RNA level <400 c/mL was assessed at Week 48 and Week 96.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 48 and Week 96

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[5]	411		
Units: Participants				
Week 48	369	356		
Week 96	338	321		

Notes:

[5] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in plasma HIV-1 RNA over time

End point title	Change from Baseline in plasma HIV-1 RNA over time
-----------------	--

End point description:

Change from Baseline in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as the measurements performed on Day 1. Change

from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).

End point type	Secondary
End point timeframe:	
Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96	

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[6]	411		
Units: log10 c/mL				
arithmetic mean (standard deviation)				
Baseline n=411, 411	4.538 (± 0.7258)	4.599 (± 0.7048)		
Week 4, n=402, 406	-2.817 (± 0.6198)	-2.801 (± 0.6041)		
Week 8, n=397, 402	-2.897 (± 0.6837)	-2.886 (± 0.6754)		
Week 12, n=396, 395	-2.908 (± 0.6863)	-2.918 (± 0.6834)		
Week 16, n=395, 388	-2.917 (± 0.6949)	-2.943 (± 0.6841)		
Week 24, n=393, 390	-2.896 (± 0.7889)	-2.933 (± 0.7398)		
Week 32, n=386, 377	-2.907 (± 0.7609)	-2.947 (± 0.7613)		
Week 40, n=375, 358	-2.920 (± 0.7219)	-2.946 (± 0.6700)		
Week 48, n=374, 358	-2.915 (± 0.7237)	-2.942 (± 0.6737)		
Week 60, n=366, 355	-2.912 (± 0.7344)	-2.937 (± 0.6685)		
Week 72, n=361, 350	-2.917 (± 0.7261)	-2.932 (± 0.6728)		
Week 84, n=352, 338	-2.932 (± 0.7073)	-2.916 (± 0.6646)		
Week 96, n=342, 329	-2.938 (± 0.7004)	-2.901 (± 0.7072)		

Notes:

[6] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute values in plasma HIV-1 RNA over time

End point title	Absolute values in plasma HIV-1 RNA over time
End point description:	
Absolute values in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).	
End point type	Secondary

End point timeframe:

Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[7]	411		
Units: log ₁₀ c/mL				
arithmetic mean (standard deviation)				
Baseline n=411, 411	4.538 (± 0.7258)	4.599 (± 0.7048)		
Week 4, n=402, 406	1.718 (± 0.2593)	1.800 (± 0.4095)		
Week 8, n=397, 402	1.646 (± 0.2006)	1.709 (± 0.3791)		
Week 12, n=396, 395	1.626 (± 0.1323)	1.672 (± 0.3125)		
Week 16, n=395, 388	1.620 (± 0.1252)	1.648 (± 0.2647)		
Week 24, n=393, 390	1.643 (± 0.2950)	1.655 (± 0.3476)		
Week 32, n=386, 377	1.620 (± 0.1917)	1.636 (± 0.2721)		
Week 40, n=375, 358	1.603 (± 0.0821)	1.601 (± 0.0784)		
Week 48, n=374, 358	1.606 (± 0.0866)	1.599 (± 0.0582)		
Week 60, n=366, 355	1.605 (± 0.1134)	1.599 (± 0.0560)		
Week 72, n=361, 350	1.601 (± 0.0803)	1.605 (± 0.0836)		
Week 84, n=352, 338	1.607 (± 0.1337)	1.614 (± 0.1279)		
Week 96, n=342, 329	1.599 (± 0.830)	1.630 (± 0.2515)		

Notes:

[7] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in cluster of differentiation (CD)4+ cell counts over time

End point title	Change from Baseline in cluster of differentiation (CD)4+ cell counts over time
-----------------	---

End point description:

CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the participants disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start ART. Changes from Baseline in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).

End point type	Secondary
End point timeframe:	
Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96	

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[8]	411		
Units: Cells per cubic millimeter (cells/mm ³)				
arithmetic mean (standard deviation)				
Baseline n=411, 411	379.2 (± 178.32)	374.3 (± 163.37)		
Week 4, n=398, 403	93.3 (± 116.27)	97.2 (± 129.35)		
Week 8, n=398, 402	121.6 (± 127.97)	126.6 (± 134.59)		
Week 12, n=392, 397	130.7 (± 131.49)	145.1 (± 144.08)		
Week 16, n=394, 392	155.1 (± 137.23)	173.0 (± 159.10)		
Week 24, n=392, 389	199.3 (± 161.23)	204.2 (± 162.28)		
Week 32, n=384, 375	223.4 (± 165.30)	241.3 (± 167.64)		
Week 40, n=371, 357	224.1 (± 173.59)	239.8 (± 173.33)		
Week 48, n=374, 357	238.9 (± 171.81)	257.5 (± 178.69)		
Week 60, n=367, 355	247.8 (± 184.11)	264.2 (± 188.63)		
Week 72, n=360, 350	247.8 (± 168.37)	278.6 (± 182.76)		
Week 84, n=351, 338	281.3 (± 175.07)	292.9 (± 199.42)		
Week 96, n=343, 328	292.2 (± 195.70)	286.2 (± 192.45)		

Notes:

[8] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute values in CD4+ cell counts over time

End point title	Absolute values in CD4+ cell counts over time
End point description:	
CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy absolute values in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).	
End point type	Secondary

End point timeframe:

Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[9]	411		
Units: cells/mm ³				
arithmetic mean (standard deviation)				
Baseline n=411, 411	379.2 (± 172.32)	374.3 (± 163.37)		
Week 4, n=398, 403	474.2 (± 199.06)	471.8 (± 191.02)		
Week 8, n=398, 402	502.3 (± 205.15)	502.4 (± 187.99)		
Week 12, n=392, 397	513.3 (± 218.75)	518.3 (± 195.59)		
Week 16, n=394, 392	536.4 (± 219.47)	550.1 (± 221.77)		
Week 24, n=392, 389	582.0 (± 232.93)	580.8 (± 218.76)		
Week 32, n=384, 375	606.5 (± 242.95)	618.7 (± 237.56)		
Week 40, n=371, 357	609.1 (± 239.11)	623.1 (± 234.82)		
Week 48, n=374, 357	623.8 (± 247.82)	641.2 (± 241.75)		
Week 60, n=367, 355	635.6 (± 241.27)	648.5 (± 238.99)		
Week 72, n=360, 350	635.2 (± 237.78)	664.0 (± 239.86)		
Week 84, n=351, 338	668.0 (± 246.50)	677.5 (± 249.64)		
Week 96, n=343, 328	679.8 (± 257.89)	672.4 (± 237.54)		

Notes:

[9] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated post-Baseline HIV-associated conditions and progression, excluding recurrences

End point title	Number of participants with the indicated post-Baseline HIV-associated conditions and progression, excluding recurrences
-----------------	--

End point description:

Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline to a CDC CAT C event (EV); CDC CAT B at Baseline to a CDC CAT C

EV; CDC CAT C at Baseline to a new CDC CAT C EV; or CDC CAT A, B, or C at Baseline to death.

End point type	Secondary
End point timeframe:	
From Baseline until Week 96	

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[10]	411		
Units: Participants				
Any category condition	10	8		
Any Category B condition	3	3		
Any Category C condition	6	4		
Any death	1	1		
Progression from CAT A to CAT C	4	2		
Progression from CAT B to CAT C	3	1		
Progression from CAT C to new CAT C	0	1		
Progression from CAT A, B, or C to death	1	1		

Notes:

[10] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated Grade 1 to 4 clinical chemistry and hematology toxicities/laboratory adverse events (AEs)

End point title	Number of participants with the indicated Grade 1 to 4 clinical chemistry and hematology toxicities/laboratory adverse events (AEs)
-----------------	---

End point description:

All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), carbon dioxide (CO₂) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hyponatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxicities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Safety Population: all participants who received at least one dose of investigational product

End point type	Secondary
End point timeframe:	
From Baseline until Week 96	

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	411 ^[11]	411		
Units: Participants				
ALT	57	70		
ALP	7	15		
AST	67	75		
CO2 content/bicarbonate	58	67		
Cholesterol	90	73		
CK	61	47		
Creatinine	11	7		
Hyperglycaemia	70	87		
Hyperkalemia	7	4		
Hyponatremia	4	6		
Hypoglycaemia	17	27		
Hypokalemia	10	15		
Hyponatremia	34	48		
LDL cholesterol calculation	74	49		
Lipase	55	62		
Phosphorus, inorganic	65	71		
Total bilirubin	27	24		
Triglycerides	7	8		
Hemoglobin	10	5		
Platelet count	19	19		
Total neutrophils	54	48		
White Blood Cell count	19	7		

Notes:

[11] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the plasma concentration-time curve from time zero to time tau [AUC(0-tau)] of DTG

End point title	Area under the plasma concentration-time curve from time zero to time tau [AUC(0-tau)] of DTG
-----------------	---

End point description:

AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. The predicted individual AUC(0-tau) were obtained from the final population PK model by an empirical Bayes estimation. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hours post-dose was completed at Week 4, then the 4 to 12 hour post-dose must be obtained at Week 48, and vice versa. The Pharmacokinetic (PK) Concentration Population comprised of all participants who received DTG, had undergone PK sampling during the study, and provided evaluable DTG plasma concentration data.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 4, Week 24, and Week 48

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	403 ^[12]	0 ^[13]		
Units: Micrograms*hour per milliliter (µg*hr/mL)				
geometric mean (geometric coefficient of variation)	53.6 (± 26.8)	()		

Notes:

[12] - PK Concentration Population

[13] - No participants were analyzed in this arm.

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum plasma concentration (C_{max}) and concentration at the end of a dosing interval (C_{tau}) of DTG

End point title	Maximum plasma concentration (C _{max}) and concentration at the end of a dosing interval (C _{tau}) of DTG
-----------------	---

End point description:

The C_{max} and C_{tau} of DTG were assessed at Week 48. The predicted individual C_{max} and C_{tau} were obtained from the final population PK model by simulation of the concentration-time profiles. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hour post-dose was completed at Week 4, then the 4 to 12 hour post-dose must be obtained at Week 48, and vice versa.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 4, Week 24, and Week 48

End point values	DTG 50 mg once a day	RTG 400 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	403 ^[14]	0 ^[15]		
Units: Micrograms per milliliter (µg/mL)				
geometric mean (geometric coefficient of variation)				
C _{max}	3.69 (± 19.6)	()		
C _{tau}	1.10 (± 46.5)	()		

Notes:

[14] - PK Concentration Population

[15] - No participants were analyzed for this arm.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the study (up to a median of 1267 days).

Adverse event reporting additional description:

AEs and non-serious AEs were collected in members of the Safety Population, which comprised of all participants who received at least one dose of investigational product.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

Reporting groups

Reporting group title	DTG 50mg once a day
-----------------------	---------------------

Reporting group description:

Participants received DTG 50 mg one a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.

Reporting group title	DTG 50mg once a day (Open Label)
-----------------------	----------------------------------

Reporting group description:

Participants who successfully completed 96 weeks of double blind phase continued to receive DTG 50 mg once a day during open label phase, until dolutegravir was locally available commercially. Participants received DTG 50 mg once a day in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.

Reporting group title	RTG 400mg BID
-----------------------	---------------

Reporting group description:

Participants received RTG 400 mg BID in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.

Serious adverse events	DTG 50mg once a day	DTG 50mg once a day (Open Label)	RTG 400mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	41 / 411 (9.98%)	21 / 338 (6.21%)	45 / 411 (10.95%)
number of deaths (all causes)	1	0	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anogenital warts			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic malignant melanoma			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papilloma			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Thrombosis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Keratoplasty			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration			

site conditions			
Chest pain			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyserositis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	3 / 411 (0.73%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune reconstitution inflammatory syndrome			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Homicide			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erectile dysfunction			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Menorrhagia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Completed suicide			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Depression			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Laceration			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol poisoning			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional overdose			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penis injury			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Seizure			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphasia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Anal fissure			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal inflammation			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritable bowel syndrome			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic pseudocyst			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peptic ulcer			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis ulcerative			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal vein thrombosis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Costochondritis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	5 / 411 (1.22%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anal abscess			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syphilis			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute hepatitis C			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical mycobacterial infection			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Corneal abscess			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis viral			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis viral			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis tuberculous			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosyphilis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis chronic			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia cytomegaloviral			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis			

subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Secondary syphilis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	DTG 50mg once a day	DTG 50mg once a day (Open Label)	RTG 400mg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	353 / 411 (85.89%)	256 / 338 (75.74%)	344 / 411 (83.70%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	16 / 411 (3.89%)	8 / 338 (2.37%)	22 / 411 (5.35%)
occurrences (all)	17	9	24
Skin papilloma			
subjects affected / exposed	9 / 411 (2.19%)	2 / 338 (0.59%)	8 / 411 (1.95%)
occurrences (all)	10	2	10
Fibroma			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	1	1	2
Lipoma			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	1	1	2
Acrochordon			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	2	2	1
Kaposi's sarcoma			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1
Melanocytic naevus			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	1	2	0
Basal cell carcinoma			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Oral papilloma			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Seborrhoeic keratosis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Anal neoplasm			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Cervix carcinoma			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Dysplastic naevus			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Eye haemangioma			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Fibroadenoma of breast			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Fibrous histiocytoma			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Haemangioma of liver			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Haemangioma of spleen			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Keratoacanthoma			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Papilloma			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Penile wart			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Schwannoma			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Uterine leiomyoma			

subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Vascular disorders			
Hypertension			
subjects affected / exposed	7 / 411 (1.70%)	5 / 338 (1.48%)	12 / 411 (2.92%)
occurrences (all)	7	6	12
Varicose vein			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	1 / 411 (0.24%)
occurrences (all)	1	2	1
Flushing			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Haematoma			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Hot flush			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Thrombophlebitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Circulatory collapse			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Deep vein thrombosis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Phlebitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Surgical and medical procedures			
Tooth extraction			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Inguinal hernia repair			

subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Nasal septal operation			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Papilloma excision			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Tonsillectomy			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	22 / 411 (5.35%)	7 / 338 (2.07%)	24 / 411 (5.84%)
occurrences (all)	26	7	27
Pyrexia			
subjects affected / exposed	23 / 411 (5.60%)	6 / 338 (1.78%)	24 / 411 (5.84%)
occurrences (all)	30	7	26
Asthenia			
subjects affected / exposed	14 / 411 (3.41%)	7 / 338 (2.07%)	18 / 411 (4.38%)
occurrences (all)	16	7	19
Influenza like illness			
subjects affected / exposed	13 / 411 (3.16%)	7 / 338 (2.07%)	9 / 411 (2.19%)
occurrences (all)	15	8	11
Chest pain			
subjects affected / exposed	5 / 411 (1.22%)	3 / 338 (0.89%)	2 / 411 (0.49%)
occurrences (all)	5	3	2
Feeling abnormal			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	3	0	2
Malaise			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	3	0	1
Local swelling			

subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	3	0	0
Oedema peripheral			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1
Pain			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	0	0	3
Peripheral swelling			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	0	1	2
Chest discomfort			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	3
Cyst			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Granuloma			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Ill-defined disorder			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Inflammation			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Mucosal dryness			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Nodule			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Suprapubic pain			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Axillary pain			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Chills			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Discomfort			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Facial pain			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Feeling cold			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Mucosal inflammation			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Oedema mucosal			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Polyp			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Swelling			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	8 / 411 (1.95%)	5 / 338 (1.48%)	7 / 411 (1.70%)
occurrences (all)	8	7	7
Food allergy			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	0	1	3

Drug hypersensitivity subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Immune reconstitution inflammatory syndrome subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	2 / 411 (0.49%) 2
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Jarisch-Herxheimer reaction subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Social circumstances Stress at work subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Reproductive system and breast disorders Erectile dysfunction subjects affected / exposed occurrences (all)	5 / 411 (1.22%) 5	3 / 338 (0.89%) 3	6 / 411 (1.46%) 6
Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	2 / 338 (0.59%) 2	1 / 411 (0.24%) 1
Cervical dysplasia subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	2 / 338 (0.59%) 2	0 / 411 (0.00%) 0
Prostatitis subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	2 / 411 (0.49%) 2
Gynaecomastia subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Menorrhagia subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Sexual dysfunction			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Testicular pain			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Vaginal discharge			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Balanoposthitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Breast mass			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Breast pain			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Breast tenderness			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Endometriosis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Epididymal tenderness			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Genital lesion			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Genital rash			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Hypospermia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Menstruation irregular			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Ovarian cyst			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Penile discharge			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Pelvic discomfort			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Prostatomegaly			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Scrotal swelling			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Testicular oedema			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Testicular swelling			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Testis discomfort			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Varicocele			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Vulval ulceration			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			

subjects affected / exposed	23 / 411 (5.60%)	9 / 338 (2.66%)	22 / 411 (5.35%)
occurrences (all)	27	9	24
Oropharyngeal pain			
subjects affected / exposed	19 / 411 (4.62%)	6 / 338 (1.78%)	16 / 411 (3.89%)
occurrences (all)	22	7	19
Asthma			
subjects affected / exposed	8 / 411 (1.95%)	1 / 338 (0.30%)	4 / 411 (0.97%)
occurrences (all)	10	1	4
Rhinitis allergic			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	11 / 411 (2.68%)
occurrences (all)	2	0	13
Nasal congestion			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	5 / 411 (1.22%)
occurrences (all)	3	2	5
Rhinorrhoea			
subjects affected / exposed	2 / 411 (0.49%)	2 / 338 (0.59%)	4 / 411 (0.97%)
occurrences (all)	2	2	4
Sinus congestion			
subjects affected / exposed	3 / 411 (0.73%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	3	1	3
Epistaxis			
subjects affected / exposed	2 / 411 (0.49%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	2	2	2
Catarrh			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	0	1	2
Allergic sinusitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	2
Dysphonia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1

Lung disorder			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	2	1	0
Productive cough			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Respiratory disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Respiratory tract congestion			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Tonsillar hypertrophy			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Atelectasis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Dry throat			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Emphysema			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Laryngospasm			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Nasal dryness			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Nasal obstruction			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Nocturnal dyspnoea			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0

Pneumothorax			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Upper respiratory tract congestion			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Upper-airway cough syndrome			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Wheezing			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Psychiatric disorders			
Insomnia			
subjects affected / exposed	28 / 411 (6.81%)	6 / 338 (1.78%)	19 / 411 (4.62%)
occurrences (all)	28	6	20
Depression			
subjects affected / exposed	26 / 411 (6.33%)	8 / 338 (2.37%)	18 / 411 (4.38%)
occurrences (all)	26	8	18
Anxiety			
subjects affected / exposed	19 / 411 (4.62%)	6 / 338 (1.78%)	22 / 411 (5.35%)
occurrences (all)	19	7	24
Abnormal dreams			
subjects affected / exposed	13 / 411 (3.16%)	1 / 338 (0.30%)	8 / 411 (1.95%)
occurrences (all)	14	1	9
Sleep disorder			
subjects affected / exposed	7 / 411 (1.70%)	1 / 338 (0.30%)	8 / 411 (1.95%)
occurrences (all)	7	1	8
Libido decreased			
subjects affected / exposed	3 / 411 (0.73%)	1 / 338 (0.30%)	10 / 411 (2.43%)
occurrences (all)	3	1	10
Stress			

subjects affected / exposed	4 / 411 (0.97%)	2 / 338 (0.59%)	4 / 411 (0.97%)
occurrences (all)	4	2	4
Nightmare			
subjects affected / exposed	6 / 411 (1.46%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	6	0	2
Depressed mood			
subjects affected / exposed	4 / 411 (0.97%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	4	1	1
Panic attack			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	2	1	2
Acute stress disorder			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	0	2	2
Drug use disorder			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	1 / 411 (0.24%)
occurrences (all)	1	2	1
Burnout syndrome			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Disorientation			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	0	0	4
Euphoric mood			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Irritability			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Suicidal ideation			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1
Agitation			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Emotional disorder			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Adjustment disorder			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Adjustment disorder with depressed mood			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Aggression			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Agoraphobia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Alcoholic psychosis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Anxiety disorder			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Apathy			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Attention deficit/hyperactivity disorder			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Confusional state			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Hallucination			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Major depression			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Mental disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Mental fatigue			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Middle insomnia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Mood swings			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Nervousness			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Panic reaction			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Persistent depressive disorder			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Phobia of flying			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Sleep-related eating disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Somnambulism			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Substance-induced psychotic			

disorder			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	2
Terminal insomnia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Thinking abnormal			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Withdrawal syndrome			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	2	1	3
Cholelithiasis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Hepatitis toxic			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	3
Biliary colic			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Cholecystitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Drug-induced liver injury			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Gallbladder polyp			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Hepatic cyst			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Hepatic lesion			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Hepatitis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Hepatocellular injury			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Hepatomegaly			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	6 / 411 (1.46%)	1 / 338 (0.30%)	4 / 411 (0.97%)
occurrences (all)	8	1	10
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	4 / 411 (0.97%)
occurrences (all)	3	2	9
Weight increased			
subjects affected / exposed	4 / 411 (0.97%)	0 / 338 (0.00%)	5 / 411 (1.22%)
occurrences (all)	4	0	5
Weight decreased			
subjects affected / exposed	3 / 411 (0.73%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	4	1	3
Blood pressure increased			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	3	0	3
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 411 (0.00%)	3 / 338 (0.89%)	2 / 411 (0.49%)
occurrences (all)	0	3	2
Lipase increased			

subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	1	1	3
Transaminases increased			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	1	1	2
Blood creatinine increased			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Blood glucose increased			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Urinary sediment present			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Blood bilirubin increased			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Blood cholesterol increased			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Blood glucose decreased			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Blood testosterone decreased			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1

Heart sounds abnormal subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Human papilloma virus test positive subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Liver function test increased subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Oestradiol increased subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Parasite stool test positive subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Protein urine present subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
QRS axis abnormal subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Shigella test positive subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Streptococcus test positive subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Urine analysis abnormal subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Vitamin D decreased subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Injury, poisoning and procedural complications			

Ligament sprain			
subjects affected / exposed	6 / 411 (1.46%)	6 / 338 (1.78%)	5 / 411 (1.22%)
occurrences (all)	6	8	5
Muscle strain			
subjects affected / exposed	7 / 411 (1.70%)	3 / 338 (0.89%)	3 / 411 (0.73%)
occurrences (all)	7	3	3
Limb injury			
subjects affected / exposed	2 / 411 (0.49%)	3 / 338 (0.89%)	5 / 411 (1.22%)
occurrences (all)	2	3	5
Contusion			
subjects affected / exposed	4 / 411 (0.97%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	4	2	2
Epicondylitis			
subjects affected / exposed	4 / 411 (0.97%)	3 / 338 (0.89%)	0 / 411 (0.00%)
occurrences (all)	4	3	0
Laceration			
subjects affected / exposed	4 / 411 (0.97%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	4	0	2
Arthropod bite			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	2	1	2
Fall			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	1	2	2
Rib fracture			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	2	1	3
Skin abrasion			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	1	1	4
Bone contusion			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	3	0	1
Foot fracture			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	3	0	1

Meniscus injury			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	2	1	0
Back injury			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Concussion			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Exposure to communicable disease			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	2
Hand fracture			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Injury			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Ligament rupture			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Post-traumatic neck syndrome			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Procedural pain			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Road traffic accident			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Scar			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Tendon rupture			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1

Thermal burn			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Upper limb fracture			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Accident			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Animal bite			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Ankle fracture			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Arthropod sting			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Bone fissure			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Burns second degree			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Cartilage injury			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Ear injury			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Excoriation			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Eye contusion			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0

Eye injury			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Fracture			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Head injury			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Human bite			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Joint injury			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Joint dislocation			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Lower limb fracture			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Neck injury			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Patella fracture			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Penis injury			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Poisoning			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Post lumbar puncture syndrome			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1

Post procedural discomfort subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Post-traumatic pain subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Scratch subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Subdural haematoma subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Tendon injury subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Traumatic haematoma subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Ulnar nerve injury subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Wound subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Congenital, familial and genetic disorders			
Hereditary non-polyposis colorectal cancer syndrome subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Ichthyosis subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Kidney duplex subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Odontogenic cyst			

subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	4 / 411 (0.97%)
occurrences (all)	1	1	4
Palpitations			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	1	1	2
Tachycardia			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Cardiomyopathy			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Myocarditis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Ventricular hypokinesia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Nervous system disorders			
Headache			
subjects affected / exposed	56 / 411 (13.63%)	9 / 338 (2.66%)	55 / 411 (13.38%)
occurrences (all)	63	9	70
Dizziness			
subjects affected / exposed	24 / 411 (5.84%)	0 / 338 (0.00%)	24 / 411 (5.84%)
occurrences (all)	25	0	24
Sciatica			
subjects affected / exposed	4 / 411 (0.97%)	4 / 338 (1.18%)	7 / 411 (1.70%)
occurrences (all)	4	4	9
Migraine			
subjects affected / exposed	4 / 411 (0.97%)	1 / 338 (0.30%)	5 / 411 (1.22%)
occurrences (all)	5	1	10
Lethargy			

subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	6 / 411 (1.46%)
occurrences (all)	3	0	7
Hypoaesthesia			
subjects affected / exposed	4 / 411 (0.97%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	5	2	2
Paraesthesia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	5 / 411 (1.22%)
occurrences (all)	1	0	6
Somnolence			
subjects affected / exposed	4 / 411 (0.97%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	4	0	2
Disturbance in attention			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	4 / 411 (0.97%)
occurrences (all)	1	0	5
Dysgeusia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	4 / 411 (0.97%)
occurrences (all)	1	0	4
Facial paralysis			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	2	1	2
Amnesia			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	3	0	1
Cervicobrachial syndrome			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	1 / 411 (0.24%)
occurrences (all)	2	2	1
Memory impairment			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	1 / 411 (0.24%)
occurrences (all)	0	2	1
Syncope			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Balance disorder			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Burning sensation			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Cognitive disorder			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Dysaesthesia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	2
Neuralgia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Poor quality sleep			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Agnosia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Anosmia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Apraxia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Brain injury			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Cerebral haemorrhage			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Cervical radiculopathy			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Circadian rhythm sleep disorder			

subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Cluster headache			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Dizziness postural			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Dystonia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Hyperaesthesia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Morton's neuralgia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Nerve compression			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Peroneal nerve palsy			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Post herpetic neuralgia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Presyncope			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Sensory disturbance			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Trigeminal neuralgia			

subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Vascular headache subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Blood and lymphatic system disorders			
Lymphadenopathy subjects affected / exposed occurrences (all)	9 / 411 (2.19%) 13	3 / 338 (0.89%) 4	4 / 411 (0.97%) 4
Anaemia subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	4 / 411 (0.97%) 4
Iron deficiency anaemia subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	1 / 338 (0.30%) 1	2 / 411 (0.49%) 2
Neutropenia subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 2	0 / 338 (0.00%) 0	2 / 411 (0.49%) 2
Lymphadenitis subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Eosinophilia subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Granulocytopenia subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Leukopenia subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Polycythaemia subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Red blood cell abnormality subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1

Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Thymus disorder subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	6 / 411 (1.46%) 6	1 / 338 (0.30%) 1	5 / 411 (1.22%) 5
Tinnitus subjects affected / exposed occurrences (all)	5 / 411 (1.22%) 5	0 / 338 (0.00%) 0	4 / 411 (0.97%) 5
Ear pain subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	2 / 338 (0.59%) 2	0 / 411 (0.00%) 0
Hypoacusis subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Deafness subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	2 / 411 (0.49%) 2
Ear disorder subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Excessive cerumen production subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Eustachian tube obstruction subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
External ear inflammation subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
External ear pain			

subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Middle ear effusion subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Tympanic membrane disorder subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	0 / 338 (0.00%) 0	5 / 411 (1.22%) 5
Conjunctivitis allergic subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	1 / 338 (0.30%) 1	2 / 411 (0.49%) 2
Ocular hyperaemia subjects affected / exposed occurrences (all)	3 / 411 (0.73%) 3	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Visual acuity reduced subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	1 / 338 (0.30%) 1	1 / 411 (0.24%) 1
Chalazion subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	2 / 338 (0.59%) 2	0 / 411 (0.00%) 0
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Eye pruritus subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0

Blepharitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Cataract			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Corneal erosion			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Diplopia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Eye inflammation			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Eye pain			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Eyelids pruritus			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Hypermetropia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Keratitis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Ocular discomfort			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Photophobia			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Retinal tear			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1

Retinal haemorrhage subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Scleritis subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	58 / 411 (14.11%) 72	21 / 338 (6.21%) 25	54 / 411 (13.14%) 65
Nausea subjects affected / exposed occurrences (all)	60 / 411 (14.60%) 70	3 / 338 (0.89%) 3	55 / 411 (13.38%) 66
Abdominal pain subjects affected / exposed occurrences (all)	18 / 411 (4.38%) 21	7 / 338 (2.07%) 7	16 / 411 (3.89%) 20
Vomiting subjects affected / exposed occurrences (all)	16 / 411 (3.89%) 21	5 / 338 (1.48%) 7	18 / 411 (4.38%) 19
Constipation subjects affected / exposed occurrences (all)	15 / 411 (3.65%) 16	1 / 338 (0.30%) 1	14 / 411 (3.41%) 17
Abdominal pain upper subjects affected / exposed occurrences (all)	12 / 411 (2.92%) 13	5 / 338 (1.48%) 5	12 / 411 (2.92%) 14
Haemorrhoids subjects affected / exposed occurrences (all)	15 / 411 (3.65%) 15	5 / 338 (1.48%) 6	9 / 411 (2.19%) 9
Flatulence subjects affected / exposed occurrences (all)	12 / 411 (2.92%) 12	1 / 338 (0.30%) 1	11 / 411 (2.68%) 11
Dyspepsia subjects affected / exposed occurrences (all)	6 / 411 (1.46%) 6	2 / 338 (0.59%) 3	11 / 411 (2.68%) 11
Toothache			

subjects affected / exposed	9 / 411 (2.19%)	6 / 338 (1.78%)	3 / 411 (0.73%)
occurrences (all)	10	6	3
Gastrooesophageal reflux disease			
subjects affected / exposed	4 / 411 (0.97%)	1 / 338 (0.30%)	12 / 411 (2.92%)
occurrences (all)	4	1	12
Abdominal distension			
subjects affected / exposed	6 / 411 (1.46%)	4 / 338 (1.18%)	6 / 411 (1.46%)
occurrences (all)	6	5	7
Proctitis			
subjects affected / exposed	5 / 411 (1.22%)	4 / 338 (1.18%)	5 / 411 (1.22%)
occurrences (all)	5	4	6
Anogenital dysplasia			
subjects affected / exposed	3 / 411 (0.73%)	5 / 338 (1.48%)	4 / 411 (0.97%)
occurrences (all)	3	5	4
Abdominal discomfort			
subjects affected / exposed	10 / 411 (2.43%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	11	0	1
Anal fissure			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	6 / 411 (1.46%)
occurrences (all)	3	2	6
Gastritis			
subjects affected / exposed	4 / 411 (0.97%)	5 / 338 (1.48%)	1 / 411 (0.24%)
occurrences (all)	4	5	1
Aphthous ulcer			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	4 / 411 (0.97%)
occurrences (all)	3	2	6
Odynophagia			
subjects affected / exposed	3 / 411 (0.73%)	1 / 338 (0.30%)	4 / 411 (0.97%)
occurrences (all)	3	1	4
Rectal haemorrhage			
subjects affected / exposed	2 / 411 (0.49%)	2 / 338 (0.59%)	3 / 411 (0.73%)
occurrences (all)	2	2	3
Dental caries			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	3	0	3
Abdominal pain lower			

subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	1	1	3
Enteritis			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	1	2	2
Inguinal hernia			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	2	1	2
Anal fistula			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	2	1	1
Colitis			
subjects affected / exposed	2 / 411 (0.49%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	2	2	0
Gastrointestinal disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	1	0	3
Hiatus hernia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	0	1	3
Proctalgia			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	3	0	2
Anal haemorrhage			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1
Anal pruritus			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	3	0	0
Dry mouth			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Mouth ulceration			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1
Oesophagitis			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Abdominal tenderness			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Abnormal faeces			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Anal ulcer			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1
Anorectal discomfort			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Cheilitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Dysphagia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Food poisoning			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal pain			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Haematochezia			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Oesophageal spasm			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Oral disorder			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Abdominal rigidity			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Anal skin tags			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Anal spasm			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Anorectal disorder			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Chronic gastritis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Diverticulum			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	3
Epigastric discomfort			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Erosive duodenitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Faeces pale			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Gastric ulcer			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Gingival hypertrophy			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Gingival pain			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Gingival swelling			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Hyperchlorhydria			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Irritable bowel syndrome			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Large intestine polyp			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Lip haematoma			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Lip swelling			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Loose tooth			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Mouth cyst			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Oesophageal pain			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Oral pain			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Palatal disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Pancreatitis acute			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Palatal ulcer			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Paraesthesia oral			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Periodontal disease			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Rectal discharge			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Rectal fissure			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Saliva altered			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Salivary hypersecretion			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Tongue disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Tooth disorder			

subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Tooth impacted subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Ulcerative gastritis subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	18 / 411 (4.38%) 22	1 / 338 (0.30%) 1	19 / 411 (4.62%) 23
Pruritus subjects affected / exposed occurrences (all)	17 / 411 (4.14%) 18	5 / 338 (1.48%) 5	10 / 411 (2.43%) 10
Acne subjects affected / exposed occurrences (all)	9 / 411 (2.19%) 9	2 / 338 (0.59%) 2	8 / 411 (1.95%) 9
Eczema subjects affected / exposed occurrences (all)	7 / 411 (1.70%) 9	1 / 338 (0.30%) 1	7 / 411 (1.70%) 10
Night sweats subjects affected / exposed occurrences (all)	5 / 411 (1.22%) 5	2 / 338 (0.59%) 2	8 / 411 (1.95%) 8
Alopecia subjects affected / exposed occurrences (all)	5 / 411 (1.22%) 5	4 / 338 (1.18%) 4	4 / 411 (0.97%) 4
Seborrhoeic dermatitis subjects affected / exposed occurrences (all)	3 / 411 (0.73%) 3	1 / 338 (0.30%) 1	8 / 411 (1.95%) 9
Dry skin subjects affected / exposed occurrences (all)	5 / 411 (1.22%) 5	1 / 338 (0.30%) 1	5 / 411 (1.22%) 5
Dermatitis subjects affected / exposed occurrences (all)	3 / 411 (0.73%) 3	2 / 338 (0.59%) 2	3 / 411 (0.73%) 3

Dermatitis contact			
subjects affected / exposed	4 / 411 (0.97%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	4	1	3
Skin lesion			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	4 / 411 (0.97%)
occurrences (all)	2	1	5
Hyperhidrosis			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	3	0	3
Urticaria			
subjects affected / exposed	3 / 411 (0.73%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	3	1	2
Intertrigo			
subjects affected / exposed	4 / 411 (0.97%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	4	0	0
Photosensitivity reaction			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	2	1	1
Rosacea			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	1	0	3
Dermatitis acneiform			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	2	1	0
Erythema			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Psoriasis			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1
Rash papular			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	3	0	1
Actinic keratosis			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0

Dermatitis allergic			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Drug eruption			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Dyshidrotic eczema			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Eczema nummular			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Facial wasting			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Macule			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Neurodermatitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Pityriasis rosea			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Rash macular			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Rash pruritic			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	2
Skin fissures			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Acne conglobata			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0

Acne cystic			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Alopecia areata			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Angioedema			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Cutaneous lupus erythematosus			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Dermal cyst			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Dermatosis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Eczema asteatotic			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Hidradenitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Lentigo			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Lipoatrophy			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Mechanical urticaria			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0

Nail discolouration			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Nail ridging			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Pain of skin			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Papule			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Penile ulceration			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Pityriasis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Post inflammatory pigmentation change			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Pruritus generalised			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Rash erythematous			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Rash generalised			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Scab			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Skin burning sensation			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Skin exfoliation			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Skin hyperpigmentation			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Skin irritation			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Skin mass			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Skin plaque			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Skin ulcer			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Spider naevus			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Swelling face			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Telangiectasia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Toxic skin eruption			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Vitiligo			

subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Xeroderma subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	4 / 411 (0.97%) 5	0 / 338 (0.00%) 0	4 / 411 (0.97%) 5
Urethral discharge subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	2 / 338 (0.59%) 2	3 / 411 (0.73%) 3
Haematuria subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	0 / 338 (0.00%) 0	2 / 411 (0.49%) 2
Micturition urgency subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	1 / 338 (0.30%) 1	1 / 411 (0.24%) 1
Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	2 / 338 (0.59%) 2	1 / 411 (0.24%) 1
Leukocyturia subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	2 / 411 (0.49%) 2
Urethral pain subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Chronic kidney disease subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	1 / 338 (0.30%) 1	0 / 411 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	2 / 411 (0.49%) 2	0 / 338 (0.00%) 0	0 / 411 (0.00%) 0
Polyuria subjects affected / exposed occurrences (all)	1 / 411 (0.24%) 1	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1

Proteinuria			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Renal colic			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Glycosuria			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Microalbuminuria			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Renal impairment			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Urethral haemorrhage			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Urethral stenosis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Urinary hesitation			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Urinary retention			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Urinary tract disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Urine flow decreased			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0

Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Goitre			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Androgen deficiency			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Basedow's disease			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Hyperthyroidism			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Hypogonadism			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Thyroid mass			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	24 / 411 (5.84%)	10 / 338 (2.96%)	26 / 411 (6.33%)
occurrences (all)	27	15	29
Arthralgia			
subjects affected / exposed	11 / 411 (2.68%)	7 / 338 (2.07%)	14 / 411 (3.41%)
occurrences (all)	13	8	17
Tendonitis			
subjects affected / exposed	7 / 411 (1.70%)	5 / 338 (1.48%)	9 / 411 (2.19%)
occurrences (all)	7	5	9
Myalgia			
subjects affected / exposed	10 / 411 (2.43%)	3 / 338 (0.89%)	7 / 411 (1.70%)
occurrences (all)	10	3	7
Pain in extremity			

subjects affected / exposed	7 / 411 (1.70%)	1 / 338 (0.30%)	10 / 411 (2.43%)
occurrences (all)	7	1	11
Musculoskeletal pain			
subjects affected / exposed	5 / 411 (1.22%)	2 / 338 (0.59%)	7 / 411 (1.70%)
occurrences (all)	5	2	7
Osteopenia			
subjects affected / exposed	2 / 411 (0.49%)	5 / 338 (1.48%)	7 / 411 (1.70%)
occurrences (all)	2	5	7
Neck pain			
subjects affected / exposed	4 / 411 (0.97%)	2 / 338 (0.59%)	5 / 411 (1.22%)
occurrences (all)	4	2	8
Muscle spasms			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	4 / 411 (0.97%)
occurrences (all)	3	2	4
Musculoskeletal chest pain			
subjects affected / exposed	5 / 411 (1.22%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	6	1	3
Bursitis			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	3	2	2
Osteoarthritis			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	1 / 411 (0.24%)
occurrences (all)	3	3	1
Osteoporosis			
subjects affected / exposed	1 / 411 (0.24%)	3 / 338 (0.89%)	2 / 411 (0.49%)
occurrences (all)	1	3	2
Flank pain			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	2	1	5
Spinal osteoarthritis			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	2	1	1
Intervertebral disc protrusion			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	1	2	0
Joint swelling			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Muscle contracture			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	2	1	0
Plantar fasciitis			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	1 / 411 (0.24%)
occurrences (all)	0	2	1
Synovial cyst			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	1	2	0
Intervertebral disc disorder			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Limb discomfort			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Musculoskeletal discomfort			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Rotator cuff syndrome			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Spinal pain			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Arthritis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Bone erosion			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Bone pain			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Chondritis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Costochondritis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Dupuytren's contracture			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Enthesopathy			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Fasciitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Fistula			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Foot deformity			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Gouty arthritis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Groin pain			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Intervertebral disc degeneration			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Jaw disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Joint stiffness			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Muscle fatigue			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Muscle tightness			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Muscle twitching			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Myosclerosis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Myositis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Osteochondrosis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	3
Osteonecrosis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Periarthritis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Plantar fascial fibromatosis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Psoriatic arthropathy			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Scoliosis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Torticollis			

subjects affected / exposed occurrences (all)	0 / 411 (0.00%) 0	0 / 338 (0.00%) 0	1 / 411 (0.24%) 1
Infections and infestations			
Viral upper respiratory tract infection			
subjects affected / exposed	54 / 411 (13.14%)	24 / 338 (7.10%)	54 / 411 (13.14%)
occurrences (all)	73	27	77
Upper respiratory tract infection			
subjects affected / exposed	34 / 411 (8.27%)	27 / 338 (7.99%)	31 / 411 (7.54%)
occurrences (all)	43	36	38
Syphilis			
subjects affected / exposed	24 / 411 (5.84%)	24 / 338 (7.10%)	28 / 411 (6.81%)
occurrences (all)	25	30	30
Bronchitis			
subjects affected / exposed	24 / 411 (5.84%)	15 / 338 (4.44%)	22 / 411 (5.35%)
occurrences (all)	33	16	25
Sinusitis			
subjects affected / exposed	25 / 411 (6.08%)	12 / 338 (3.55%)	16 / 411 (3.89%)
occurrences (all)	36	19	18
Gastroenteritis			
subjects affected / exposed	18 / 411 (4.38%)	10 / 338 (2.96%)	18 / 411 (4.38%)
occurrences (all)	21	11	23
Influenza			
subjects affected / exposed	16 / 411 (3.89%)	7 / 338 (2.07%)	22 / 411 (5.35%)
occurrences (all)	17	7	23
Pharyngitis			
subjects affected / exposed	23 / 411 (5.60%)	9 / 338 (2.66%)	14 / 411 (3.41%)
occurrences (all)	31	9	16
Respiratory tract infection			
subjects affected / exposed	19 / 411 (4.62%)	5 / 338 (1.48%)	12 / 411 (2.92%)
occurrences (all)	19	9	14
Rhinitis			
subjects affected / exposed	13 / 411 (3.16%)	7 / 338 (2.07%)	13 / 411 (3.16%)
occurrences (all)	20	8	15
Oral herpes			
subjects affected / exposed	8 / 411 (1.95%)	7 / 338 (2.07%)	13 / 411 (3.16%)
occurrences (all)	9	8	17

Conjunctivitis			
subjects affected / exposed	8 / 411 (1.95%)	8 / 338 (2.37%)	11 / 411 (2.68%)
occurrences (all)	8	9	11
Urinary tract infection			
subjects affected / exposed	12 / 411 (2.92%)	4 / 338 (1.18%)	7 / 411 (1.70%)
occurrences (all)	14	4	8
Respiratory tract infection viral			
subjects affected / exposed	11 / 411 (2.68%)	4 / 338 (1.18%)	7 / 411 (1.70%)
occurrences (all)	13	6	8
Urethritis			
subjects affected / exposed	9 / 411 (2.19%)	5 / 338 (1.48%)	8 / 411 (1.95%)
occurrences (all)	10	6	10
Chlamydial infection			
subjects affected / exposed	5 / 411 (1.22%)	7 / 338 (2.07%)	9 / 411 (2.19%)
occurrences (all)	6	8	13
Gonorrhoea			
subjects affected / exposed	7 / 411 (1.70%)	8 / 338 (2.37%)	6 / 411 (1.46%)
occurrences (all)	8	9	7
Herpes zoster			
subjects affected / exposed	9 / 411 (2.19%)	2 / 338 (0.59%)	9 / 411 (2.19%)
occurrences (all)	9	2	9
Gingivitis			
subjects affected / exposed	8 / 411 (1.95%)	0 / 338 (0.00%)	11 / 411 (2.68%)
occurrences (all)	8	0	11
Tonsillitis			
subjects affected / exposed	10 / 411 (2.43%)	5 / 338 (1.48%)	4 / 411 (0.97%)
occurrences (all)	10	8	4
Folliculitis			
subjects affected / exposed	6 / 411 (1.46%)	4 / 338 (1.18%)	8 / 411 (1.95%)
occurrences (all)	7	4	9
Ear infection			
subjects affected / exposed	7 / 411 (1.70%)	2 / 338 (0.59%)	7 / 411 (1.70%)
occurrences (all)	7	2	11
Genital herpes			
subjects affected / exposed	5 / 411 (1.22%)	5 / 338 (1.48%)	4 / 411 (0.97%)
occurrences (all)	6	6	5

Pneumonia			
subjects affected / exposed	8 / 411 (1.95%)	2 / 338 (0.59%)	4 / 411 (0.97%)
occurrences (all)	8	2	4
Tooth infection			
subjects affected / exposed	7 / 411 (1.70%)	3 / 338 (0.89%)	4 / 411 (0.97%)
occurrences (all)	8	3	4
Nasopharyngitis			
subjects affected / exposed	6 / 411 (1.46%)	3 / 338 (0.89%)	4 / 411 (0.97%)
occurrences (all)	7	3	4
Secondary syphilis			
subjects affected / exposed	4 / 411 (0.97%)	5 / 338 (1.48%)	4 / 411 (0.97%)
occurrences (all)	4	5	5
Cellulitis			
subjects affected / exposed	5 / 411 (1.22%)	2 / 338 (0.59%)	4 / 411 (0.97%)
occurrences (all)	5	2	5
Herpes simplex			
subjects affected / exposed	1 / 411 (0.24%)	3 / 338 (0.89%)	7 / 411 (1.70%)
occurrences (all)	1	5	8
Herpes virus infection			
subjects affected / exposed	3 / 411 (0.73%)	3 / 338 (0.89%)	5 / 411 (1.22%)
occurrences (all)	3	5	8
Onychomycosis			
subjects affected / exposed	4 / 411 (0.97%)	3 / 338 (0.89%)	4 / 411 (0.97%)
occurrences (all)	5	3	4
Fungal skin infection			
subjects affected / exposed	5 / 411 (1.22%)	0 / 338 (0.00%)	5 / 411 (1.22%)
occurrences (all)	5	0	5
Urethritis gonococcal			
subjects affected / exposed	2 / 411 (0.49%)	3 / 338 (0.89%)	5 / 411 (1.22%)
occurrences (all)	2	3	5
Viral infection			
subjects affected / exposed	6 / 411 (1.46%)	0 / 338 (0.00%)	4 / 411 (0.97%)
occurrences (all)	6	0	4
Furuncle			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	4 / 411 (0.97%)
occurrences (all)	3	2	5

Otitis externa			
subjects affected / exposed	1 / 411 (0.24%)	3 / 338 (0.89%)	5 / 411 (1.22%)
occurrences (all)	1	3	7
Tooth abscess			
subjects affected / exposed	4 / 411 (0.97%)	2 / 338 (0.59%)	3 / 411 (0.73%)
occurrences (all)	4	3	3
Tinea infection			
subjects affected / exposed	5 / 411 (1.22%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	5	0	3
Anal chlamydia infection			
subjects affected / exposed	3 / 411 (0.73%)	3 / 338 (0.89%)	1 / 411 (0.24%)
occurrences (all)	3	3	1
Lymphogranuloma venereum			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	5 / 411 (1.22%)
occurrences (all)	0	2	5
Otitis media			
subjects affected / exposed	4 / 411 (0.97%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	4	1	4
Skin infection			
subjects affected / exposed	2 / 411 (0.49%)	3 / 338 (0.89%)	2 / 411 (0.49%)
occurrences (all)	2	3	2
Tinea versicolour			
subjects affected / exposed	3 / 411 (0.73%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	3	2	2
Acarodermatitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	5 / 411 (1.22%)
occurrences (all)	1	0	5
Laryngitis			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	3 / 411 (0.73%)
occurrences (all)	2	1	3
Anal abscess			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	2	1	3
Erysipelas			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	2	1	2

Genital infection fungal			
subjects affected / exposed	1 / 411 (0.24%)	4 / 338 (1.18%)	0 / 411 (0.00%)
occurrences (all)	1	5	0
Infection			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	3	0	2
Labyrinthitis			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	2	1	2
Proctitis gonococcal			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	1	2	2
Subcutaneous abscess			
subjects affected / exposed	3 / 411 (0.73%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	3	1	1
Tinea cruris			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	1	2	2
Fungal infection			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	3 / 411 (0.73%)
occurrences (all)	1	0	3
Lower respiratory tract infection			
subjects affected / exposed	2 / 411 (0.49%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	2	4	0
Orchitis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	1	1	2
Pharyngitis streptococcal			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	1	1	2
Rash pustular			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	2 / 411 (0.49%)
occurrences (all)	0	2	2
Staphylococcal infection			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	2	0	2

Tinea pedis			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	2	1	1
Abscess			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	4	0	1
Acute hepatitis C			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Acute sinusitis			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1
Balanitis candida			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Cystitis			
subjects affected / exposed	3 / 411 (0.73%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	3	0	0
Epididymitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Gastroenteritis viral			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Gastrointestinal infection			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Giardiasis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Helicobacter infection			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	2
Hordeolum			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	1	0	4

Localised infection			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	2 / 411 (0.49%)
occurrences (all)	0	1	2
Lung infection			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	3	1	0
Oral candidiasis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Parotitis			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	2	1	0
Pharyngotonsillitis			
subjects affected / exposed	1 / 411 (0.24%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	1	2	0
Pilonidal cyst			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	2	1	0
Primary syphilis			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	1 / 411 (0.24%)
occurrences (all)	0	2	1
Tracheitis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Angular cheilitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Beta haemolytic streptococcal infection			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Cervicitis			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Chronic sinusitis			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	2
Dermatophytosis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Eye infection			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Gastroenteritis shigella			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Genital herpes simplex			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Genital infection bacterial			
subjects affected / exposed	0 / 411 (0.00%)	2 / 338 (0.59%)	0 / 411 (0.00%)
occurrences (all)	0	2	0
Helicobacter gastritis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Hepatitis A			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Hepatitis C			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Infected bite			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	3
Infection parasitic			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Molluscum contagiosum			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Oral infection			

subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Parasitic gastroenteritis			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	1	1	0
Paronychia			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	3	0	0
Proctitis chlamydial			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	1	0	1
Vulvovaginal mycotic infection			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Abscess oral			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Amoebiasis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Asymptomatic bacteriuria			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Bacterial disease carrier			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Bacterial infection			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Bacterial vaginosis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Bacteriuria			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Body tinea			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	2
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Campylobacter infection			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Carbuncle			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	2	0	0
Cervicitis human papilloma virus			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Chronic hepatitis C			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Chronic tonsillitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Clostridium difficile colitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Conjunctivitis viral			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Dysentery			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Ear infection fungal			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Enterobiasis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Enterovirus infection			

subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis clostridial			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Gastrointestinal viral infection			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Genitourinary chlamydia infection			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Genitourinary tract infection			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Groin abscess			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Hepatitis E			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Hepatitis viral			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Impetigo			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Infected cyst			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Latent syphilis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Latent tuberculosis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Lung abscess			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Nail infection			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Ophthalmic herpes simplex			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Oral viral infection			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal gonococcal infection			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Papilloma viral infection			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Pericoronitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Periorbital cellulitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Peritonsillar abscess			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Pharyngitis bacterial			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Pneumonia cytomegaloviral			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Post procedural infection			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Proctitis bacterial			

subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Pulpitis dental			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Pyelonephritis chronic			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Pyuria			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Scrotal abscess			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	2
Sexually transmitted disease			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Sialoadenitis			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Sinobronchitis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Sycosis barbae			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Tonsillitis bacterial			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Tonsillitis streptococcal			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Urethritis chlamydial			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection bacterial			

subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Vaginitis gardnerella			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Viral pharyngitis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Vulvovaginal candidiasis			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Yersinia infection			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Vitamin D deficiency			
subjects affected / exposed	7 / 411 (1.70%)	7 / 338 (2.07%)	6 / 411 (1.46%)
occurrences (all)	7	7	6
Decreased appetite			
subjects affected / exposed	6 / 411 (1.46%)	1 / 338 (0.30%)	8 / 411 (1.95%)
occurrences (all)	6	1	9
Hyperglycaemia			
subjects affected / exposed	0 / 411 (0.00%)	4 / 338 (1.18%)	0 / 411 (0.00%)
occurrences (all)	0	4	0
Hypophosphataemia			
subjects affected / exposed	1 / 411 (0.24%)	3 / 338 (0.89%)	0 / 411 (0.00%)
occurrences (all)	1	5	0
Gout			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Hypercholesterolaemia			
subjects affected / exposed	2 / 411 (0.49%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	2	1	0
Hyperlipidaemia			
subjects affected / exposed	2 / 411 (0.49%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	2	0	1

Iron deficiency			
subjects affected / exposed	1 / 411 (0.24%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	1	1	1
Dyslipidaemia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	1 / 411 (0.24%)
occurrences (all)	0	1	1
Increased appetite			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	2 / 411 (0.49%)
occurrences (all)	0	0	2
Alcohol intolerance			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Body fat disorder			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Dehydration			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Diabetes mellitus			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Folate deficiency			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Food intolerance			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Hyperlipasaemia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Hypertriglyceridaemia			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0

Hypovitaminosis			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Lactase deficiency			
subjects affected / exposed	0 / 411 (0.00%)	1 / 338 (0.30%)	0 / 411 (0.00%)
occurrences (all)	0	1	0
Obesity			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Polydipsia			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 411 (0.24%)	0 / 338 (0.00%)	0 / 411 (0.00%)
occurrences (all)	1	0	0
Vitamin B12 deficiency			
subjects affected / exposed	0 / 411 (0.00%)	0 / 338 (0.00%)	1 / 411 (0.24%)
occurrences (all)	0	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 October 2010	Amendment 01: Country Specific Amendment for the United Kingdom.
14 January 2011	Amendment 02: This amendment included reference to an Independent Data Monitoring Committee (IDMC) which regularly review targeted safety information. Additionally, standard hematology and clinical chemistry laboratory assessments were made required for all participants at the Week 2 study visit. Minor clarifications and corrections were incorporated.
10 October 2011	Amendment 03: This amendment allowed for a change in the management of participants with protocol-defined virologic failure. Additional follow-up assessments were added to the Liver Chemistry Stopping criteria panel.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported